Ensysce Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Ensysce Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 12,739% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-25.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 60% of Healthcare companies in United States.
Cash Cushion Ratio
+40%Cash, after subtracting all debt, equals 40% of its market value (net cash).
Higher than 74% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Ensysce Biosciences, Inc. made a loss over the last year. Ensysce Biosciences, Inc. owes $1.38 for every $1 it owns. Ensysce Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossEnsysce Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-12.72Ensysce Biosciences, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$10 MThe total market value of all of Ensysce Biosciences, Inc.'s shares at today's price (share price × number of shares), smaller than 88% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
NegativeEnsysce Biosciences, Inc.'s net worth is negative ($1 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-1295.1%Ensysce Biosciences, Inc. lost 1295.1% of its shareholders' money over the last year, lower than 98% of Healthcare companies in United States.
Owes vs Owns
1.38×Ensysce Biosciences, Inc. owes $1.38 for every $1 it owns, so it owes more than it owns, higher than 93% of Healthcare companies in United States.
Dividend yield
NoneEnsysce Biosciences, Inc. does not currently pay a dividend.
Profit growth
LossEnsysce Biosciences, Inc. made a loss in each of the last two years.
Interest cover
Not coveredEnsysce Biosciences, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashEnsysce Biosciences, Inc. held $4 M more cash than debt (net cash) at Dec 2025.
Questions
What is Ensysce Biosciences, Inc.'s return on equity?
Ensysce Biosciences, Inc. lost 1295.1% of its shareholders' money over the last year, lower than 98% of Healthcare companies in United States.
How much does Ensysce Biosciences, Inc. owe compared with what it owns?
Ensysce Biosciences, Inc. owes $1.38 for every $1 it owns, so it owes more than it owns, higher than 93% of Healthcare companies in United States.
Does Ensysce Biosciences, Inc. pay a dividend?
No. Ensysce Biosciences, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.